阿司匹林在川崎病治疗中的儿科专家共识

doi:10.7499/j.issn.1008-8830.2203190

PDF(629 KB)

HTML

中国当代儿科杂志 ›› 2022, Vol. 24 ›› Issue (6) : 597-603. DOI: 10.7499/j.issn.1008-8830.2203190

标准·方案·指南

阿司匹林在川崎病治疗中的儿科专家共识

陕西省川崎病诊疗中心/陕西省人民医院儿童病院, 上海交通大学附属儿童医院, 首都医科大学附属北京儿童医院, 中国医科大学附属盛京医院, 延安大学附属医院, 中国妇幼健康研究会儿科能力建设专委会, 中国医师协会儿科医师分会普儿科学组, 上海合作组织医院合作联盟儿科国际交流合作中心, 《中国当代儿科杂志》编辑部

作者信息 +

Pediatric expert consensus on the application of aspirin in Kawasaki disease

Shaanxi Province Diagnosis and Treatment Center of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital, Children's Hospital of Shanghai Jiao Tong University, Beijing Children's Hospital of Capital Medical University, Shengjing Hospital of China Medical University, Affiliated Hospital of Yan'an University, Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association, General Pediatric Group of Pediatrician Branch of Chinese Medical Doctor Association, Pediatric International Exchange and Cooperation Center, Shanghai Cooperation Organization Hospital Cooperation Alliance, Editorial Board of Chinese Journal of Contemporary Pediatrics

Author information +

文章历史 +

摘要

川崎病（Kawasaki disease，KD）是5岁以下儿童常见后天获得性心脏病之一，是一种急性全身性血管炎。经过近60年的研究，静脉注射免疫球蛋白（intravenous immunoglobulin，IVIG）联合阿司匹林（aspirin，Asp）口服成为急性期KD预防冠状动脉病变（coronary artery lesion，CAL）的一线治疗。然而，Asp的作用和最佳剂量仍然存在争议。该共识基于KD治疗的国内外最新的研究成果，并经过国内儿科专家充分讨论而制定，对Asp在KD中一线治疗的使用剂量、用法、疗程等提出了推荐意见。

Abstract

Kawasaki disease (KD) is one of the common acquired heart diseases in children aged <5 years and is an acute systemic vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for the prevention of coronary artery lesion in acute KD; however, there are still controversies over the role and optimal dose of aspirin. The consensus was formulated based on the latest research findings of KD treatment in China and overseas and comprehensive discussion of pediatric experts in China and put forward recommendations on the dose, usage, and course of aspirin treatment in the first-line treatment of KD.

导出引用

陕西省川崎病诊疗中心/陕西省人民医院儿童病院, 上海交通大学附属儿童医院, 首都医科大学附属北京儿童医院, 中国医科大学附属盛京医院, 延安大学附属医院, 中国妇幼健康研究会儿科能力建设专委会, 中国医师协会儿科医师分会普儿科学组, 上海合作组织医院合作联盟儿科国际交流合作中心, 《中国当代儿科杂志》编辑部. 阿司匹林在川崎病治疗中的儿科专家共识[J]. 中国当代儿科杂志. 2022, 24(6): 597-603 https://doi.org/10.7499/j.issn.1008-8830.2203190

Shaanxi Province Diagnosis and Treatment Center of Kawasaki Disease/Children's Hospital of Shaanxi ProvincialPeople's Hospital, Children's Hospital of Shanghai Jiao Tong University, Beijing Children's Hospital of Capital MedicalUniversity, Shengjing Hospital of China Medical University, Affiliated Hospital of Yan'an University, Expert Committeeof Advanced Training for Pediatrician, China Maternal and Children's Health Association, General Pediatric Group ofPediatrician Branch of Chinese Medical Doctor Association, Pediatric International Exchange and Cooperation Center,Shanghai Cooperation Organization Hospital Cooperation Alliance, Editorial Board of Chinese Journal ofContemporary Pediatrics. Pediatric expert consensus on the application of aspirin in Kawasaki disease[J]. Chinese Journal of Contemporary Pediatrics. 2022, 24(6): 597-603 https://doi.org/10.7499/j.issn.1008-8830.2203190

参考文献

1 Xie LP, Yan WL, Huang M, et al. Epidemiologic features of Kawasaki disease in Shanghai from 2013 through 2017[J]. J Epidemiol, 2020, 30(10): 429-435. PMID: 31548437. PMCID: PMC7492704. DOI: 10.2188/jea.JE20190065.
2 Makino N, Nakamura Y, Yashiro M, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016[J]. Pediatr Int, 2019, 61(4): 397-403. PMID: 30786118. DOI: 10.1111/ped.13809.
3 Kim GB, Park S, Eun LY, et al. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012-2014[J]. Pediatr Infect Dis J, 2017, 36(5): 482-485. PMID: 27997519. DOI: 10.1097/INF.0000000000001474.
4 Newburger JW, Takahashi M, Burns JC. Kawasaki disease[J]. J Am Coll Cardiol, 2016, 67(14): 1738-1749. PMID: 27056781. DOI: 10.1016/j.jacc.2015.12.073.
5 Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2003)[J]. J Cardiol, 2004, 43(4): 263-283. PMID: 15125385.
6 Hsieh KS, Weng KP, Lin CC, et al. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited[J]. Pediatrics, 2004, 114(6): e689-e693. PMID: 15545617. DOI: 10.1542/peds.2004-1037.
7 闫辉, 杜军保. 川崎病的临床诊治探索任重道远[J]. 中国实用儿科杂志, 2017, 32(8): 561-564. DOI: 10.19538/j.ek2017080601.
8 何岚, 刘芳, 黄国英, 等. 选择性冠状动脉造影在儿童川崎病合并严重冠状动脉病变中的应用[J]. 中华儿科杂志, 2019, 57(2): 108-112. PMID: 30695884. DOI: 10.3760/cma.j.issn.0578-1310.2019.02.009.
9 Ito Y, Matsui T, Abe K, et al. Aspirin dose and treatment outcomes in Kawasaki disease: a historical control study in Japan[J]. Front Pediatr, 2020, 8: 249. PMID: 32478021. PMCID: PMC7241278. DOI: 10.3389/fped.2020.00249.
10 Roberts G, Baker M, Leiblich H, et al. Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis[J]. Intern Med J, 2022, 52(2): 318-321. PMID: 35187830. DOI: 10.1111/imj.15687.
11 中国医师协会儿科医师分会风湿免疫学组, 中国儿童免疫与健康联盟, 《中国实用儿科杂志》编辑委员会. 儿童风湿性疾病相关巨噬细胞活化综合征诊断与治疗专家共识之一——总论篇[J]. 中国实用儿科杂志, 2020, 35(11): 825-831. DOI: 10.19538/j.ek2020110601.
12 Fukazawa R, Kobayashi J, Ayusawa M, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease[J]. Circ J, 2020, 84(8): 1348-1407. PMID: 32641591. DOI: 10.1253/circj.CJ-19-1094.
13 Barrios Tascón A, Centeno Malfaz F, Rojo Sombrero H, et al. National consensus on the cardiological treatment and follow-up of Kawasaki disease[J]. An Pediatr (Engl Ed), 2018, 89(3): 188.e1-188.e22. PMID: 29778491. DOI: 10.1016/j.anpedi.2018.04.003.
14 McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999. PMID: 28356445. DOI: 10.1161/CIR.0000000000000484.
15 Marchesi A, Rigante D, Cimaz R, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease[J]. Ital J Pediatr, 2021, 47(1): 16. PMID: 33494789. PMCID: PMC7830049. DOI: 10.1186/s13052-021-00962-4.
16 Laster J, Satoskar R. Aspirin-induced acute liver injury[J]. ACG Case Rep J, 2014, 2(1): 48-49. PMID: 26157904. PMCID: PMC4435341. DOI: 10.14309/crj.2014.81.
17 Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment of Kawasaki disease in children[J]. Cochrane Database Syst Rev, 2006, 2006(4): CD004175. PMID: 17054199. PMCID: PMC8765111. DOI: 10.1002/14651858.CD004175.pub2.
18 Miyata K, Kaneko T, Morikawa Y, et al. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study[J]. Lancet Child Adolesc Health, 2018, 2(12): 855-862. PMID: 30337183. DOI: 10.1016/S2352-4642(18)30293-1.
19 Pi L, Che D, Long H, et al. Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease[J]. Drug Des Devel Ther, 2018, 12: 1353-1362. PMID: 29872260. PMCID: PMC5973383. DOI: 10.2147/DDDT.S163705.
20 Scuccimarri R. Kawasaki disease[J]. Pediatr Clin North Am, 2012, 59(2): 425-445. PMID: 22560578. DOI: 10.1016/j.pcl.2012.03.009.
21 Han Y, Hu C, Yu Y. A case of rectal ulcers during aspirin therapy in acute Kawasaki disease[J]. Pediatr Rheumatol Online J, 2020, 18(1): 24. PMID: 32183841. PMCID: PMC7076976. DOI: 10.1186/s12969-020-0414-6.
22 黄笛, 黄瑞秀, 郭晨煜, 等. 临床实践指南制定方法——证据分级与推荐强度[J]. 中国循证心血管医学杂志, 2018, 10(7): 769-776. DOI: 10.3969/j.issn.1674-4055.2018.07.01.
23 BalshemH, HelfandaM, SchunemannHJ, 等. GRADE指南: Ⅲ. 证据质量分级[J]. 中国循证医学杂志, 2011, 11(4): 451-455. DOI: 10.3969/j.issn.1672-2531.2011.04.017.
24 柳颐龄, 王献民, 陈婷婷, 等. 氯吡格雷联合阿司匹林对川崎病并发中小型冠状动脉瘤患儿抗血栓治疗的疗效及安全性研究[J]. 中国当代儿科杂志, 2019, 21(8): 801-805. PMID: 31416506. PMCID: PMC7389908. DOI: 10.7499/j.issn.1008-8830.2019.08.012.
25 Loomba RS. Comment on the paper by Suet al. entitled 'safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki disease: a meta-analysis'[J]. Cardiology, 2015, 130(3): 164-165. PMID: 25676566. DOI: 10.1159/000369879.
26 《中国国家处方集》编委会. 中国国家处方集 (化学药品与生物制品卷. 儿童版)[M]. 北京: 人民军医出版社, 2013: 207.
27 陈伟谊, 白艳甫. 儿童用药现状分析与建议[J]. 中国卫生经济, 2005, 24(12): 87-88. DOI: 10.3969/j.issn.1003-0743.2005.12.031.
28 Kobayashi T, Ayusawa M, Suzuki H, et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition)[J]. Pediatr Int, 2020, 62(10): 1135-1138. PMID: 33001522. DOI: 10.1111/ped.14326.
29 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会风湿学组, 中华医学会儿科学分会免疫学组, 等. 川崎病诊断和急性期治疗专家共识[J]. 中华儿科杂志, 2022, 60(1): 6-13. PMID: 34986616. DOI: 10.3760/cma.j.cn112140-20211018-00879.
30 许柏华, 杨薇斯, 刘清彪, 等. 两种阿司匹林减量方式用于川崎病的疗效观察[J]. 中国医院用药评价与分析, 2017, 17(7): 921-923. DOI: 10.14009/j.issn.1672-2124.2017.07.021.
31 Michihata N, Matsui H, Fushimi K, et al. Guideline-concordant treatment of Kawasaki disease with immunoglobulin and aspirin and the incidence of coronary artery aneurysm[J]. Clin Pediatr (Phila), 2015, 54(11): 1076-1080. PMID: 25573948. DOI: 10.1177/0009922814566932.
32 Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Pediatrics, 2004, 114(6): 1708-1733. PMID: 15574639. DOI: 10.1542/peds.2004-2182.
33 Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial[J]. Lancet, 2012, 379(9826): 1613-1620. PMID: 22405251. DOI: 10.1016/S0140-6736(11)61930-2.
34 Huang YH, Hsin YC, Wang LJ, et al. Treatment of Kawasaki disease: a network meta-analysis of four dosage regimens of aspirin combined with recommended intravenous immunoglobulin[J]. Front Pharmacol, 2021, 12: 725126. PMID: 34456735. PMCID: PMC8397445. DOI: 10.3389/fphar.2021.725126.
35 Kuo HC, Lo MH, Hsieh KS, et al. High-dose aspirin is associated with anemia and does not confer benefit to disease outcomes in Kawasaki disease[J]. PLoS One, 2015, 10(12): e0144603. PMID: 26658843. PMCID: PMC4686074. DOI: 10.1371/journal.pone.0144603.
36 Dhanrajani A, Yeung RSM. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease[J]. Curr Opin Rheumatol, 2017, 29(5): 547-552. PMID: 28661936. DOI: 10.1097/BOR.0000000000000425.
37 Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease[J]. Pediatrics, 2017, 139(6): e20170098. PMID: 28562282. DOI: 10.1542/peds.2017-0098.
38 Ho LGY, Curtis N. What dose of aspirin should be used in the initial treatment of Kawasaki disease?[J]. Arch Dis Child, 2017, 102(12): 1180-1182. PMID: 29066520. DOI: 10.1136/archdischild-2017-313538.
39 Galuppo J, Kowker A, Rolfs J, et al. Kawasaki disease: shedding light on a mysterious diagnosis[J]. JAAPA, 2020, 33(7): 18-22. PMID: 32520905. DOI: 10.1097/01.JAA.0000668792.41976.f2.
40 Zheng X, Yue P, Liu L, et al. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: current evidence based on a meta-analysis[J]. PLoS One, 2019, 14(5): e0217274. PMID: 31117119. PMCID: PMC6531010. DOI: 10.1371/journal.pone.0217274.
41 Suzuki T, Michihata N, Yoshikawa T, et al. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more[J]. Eur J Pediatr, 2020, 179(12): 1901-1907. PMID: 32862279. DOI: 10.1007/s00431-020-03794-2.
42 孟莉, 李晓惠, 刘京晶, 等. 阿司匹林对川崎病患儿抗血小板聚集功能的研究[J]. 中国实用儿科杂志, 2019, 34(8): 670-674. DOI: 10.19538/j.ek2019080613.
43 Moussa T, Wagner-Weiner L. Kawasaki disease: beyond IVIG and aspirin[J]. Pediatr Ann, 2019, 48(10): e400-e405. PMID: 31609999. DOI: 10.3928/19382359-20190919-01.
44 Huang X, Huang P, Zhang L, et al. Is aspirin necessary in the acute phase of Kawasaki disease?[J]. J Paediatr Child Health, 2018, 54(6): 661-664. PMID: 29271519. DOI: 10.1111/jpc.13816.
45 唐琴琴, 余唯琪. 川崎病治疗新进展[J]. 临床儿科杂志, 2013, 31(5): 488-490. DOI: 10.3969/j.issn.1000-3606.2013.05.026.
46 Jia X, Du X, Bie S, et al. What dose of aspirin should be used in the initial treatment of Kawasaki disease? A meta-analysis[J]. Rheumatology (Oxford), 2020, 59(8): 1826-1833. PMID: 32159800. DOI: 10.1093/rheumatology/keaa050.
47 Chiang MH, Liu HE, Wang JL. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review[J]. Arch Dis Child, 2021, 106(7): 662-668. PMID: 33172886. DOI: 10.1136/archdischild-2019-318245.
48 Dhanrajani A, Chan M, Pau S, et al. Aspirin dose in Kawasaki disease: the ongoing battle[J]. Arthritis Care Res (Hoboken), 2018, 70(10): 1536-1540. PMID: 29287309. DOI: 10.1002/acr.23504.
49 Kim GB, Yu JJ, Yoon KL, et al. Medium- or higher-dose acetylsalicylic acid for acute Kawasaki disease and patient outcomes[J]. J Pediatr, 2017, 184: 125-129.e1. PMID: 28043685. DOI: 10.1016/j.jpeds.2016.12.019.
50 Amarilyo G, Koren Y, Brik Simon D, et al. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?[J]. Clin Exp Rheumatol, 2017, 35 Suppl 103(1): 209-212. PMID: 28079513.
51 Platt B, Belarski E, Manaloor J, et al. Comparison of risk of recrudescent fever in children with Kawasaki disease treated with intravenous immunoglobulin and low-dose vs high-dose aspirin[J]. JAMA Netw Open, 2020, 3(1): e1918565. PMID: 31899532. PMCID: PMC6991313. DOI: 10.1001/jamanetworkopen.2019.18565.
52 Yoo JW, Kim JM, Kil HR. The outcome of short-term low-dose aspirin treatment in Kawasaki disease based on inflammatory markers[J]. Korean J Pediatr, 2017, 60(1): 24-29. PMID: 28203257. PMCID: PMC5309321. DOI: 10.3345/kjp.2017.60.1.24.
53 Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome[J]. Pediatrics, 2009, 123(5): e783-e789. PMID: 19403470. PMCID: PMC2848476. DOI: 10.1542/peds.2008-1871.
54 Zhang Q, Liao Y, Du J. Kawasaki disease shock syndrome: a report of two cases and literature review[J]. Pediatr Investig, 2019, 3(2): 81-85. PMID: 32851296. PMCID: PMC7331343. DOI: 10.1002/ped4.12127.
55 Yang HF, Chen WL, Chang CN, et al. Kawasaki disease shock syndrome: case report[J]. Paediatr Int Child Health, 2016, 36(1): 76-78. PMID: 25695906. DOI: 10.1179/2046905515Y.0000000002.
56 Wang H, Dong J, Cui X, et al. Cardiovascular system involvement[M]//Wang H. Paediatric Kawasaki Disease: Clinical Analysis and Cases. Singapore: Springer Singapore, 2021: 7-85.
57 Zheng Z, Huang Y, Wang Z, et al. Clinical features in children with Kawasaki disease shock syndrome: a systematic review and meta-analysis[J]. Front Cardiovasc Med, 2021, 8: 736352. PMID: 34621802. PMCID: PMC8491834. DOI: 10.3389/fcvm.2021.736352.
58 Asada D, Taura Y, Itoh H, et al. Acute gastrointestinal hemorrhage in Kawasaki disease occurring before aspirin therapy[J]. Pediatr Int, 2019, 61(11): 1177-1178. PMID: 31773846. DOI: 10.1111/ped.13989.
59 沈亚兵, 苏红霞. 阿司匹林致川崎病患儿肝损伤[J]. 药物不良反应杂志, 2020, 22(11): 648-649. DOI: 10.3760/cma.j.cn114015-20200112-00035.
60 Correction to: diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2019, 140(5): e181-e184. PMID: 31356128. DOI: 10.1161/CIR.0000000000000703.